On October 13, 2023, PharmaJet, Inc. closed the transaction. The company issued 4,184,214 series H preferred shares at an issue price of $3.585 per share for gross proceeds of $15,000,407.19 in the transaction. The transaction included participation from new investor Daicel Corporation.

The shares will be convertible into common shares at a fixed price of $3.584 per share. The shares carry non-cumulative and non-participating fixed dividend value of $0.287 per share per annum.